reports
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Result...
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s websi...
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Trea...
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has...
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neurop...
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be presented at the 7th Annual Meetin...
Chinese leasing company goes live with Transcend Finance in Indonesia
Chinese leasing company goes live with Transcend Finance in Indonesia ENCINO, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the successful go-live of its Transcend Finance platform for a leading Chinese leasing company, marking the customer's official launch of operations in the Indonesian market. The customer, known for offering a wide range of leasing solutions across sectors including equipment leasin...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, G...
NETSOL Technologies China Signs Strategic Agreement at the SCO Summit ...
NETSOL Technologies China Signs Strategic Agreement at the SCO Summit 2025 ENCINO, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, participated at the Shanghai Cooperation Organization (SCO) Summit in Tianjin, China this past week on July 11, 2025, where it signed a strategic cooperation agreement with Tianjin Binhai Smart Group Co., Ltd. and the Dongjiang Free Trade Port Zone Government. The partnership will focus on t...
NETSOL Technologies Appoints Ian Smith to its Board of Directors
NETSOL Technologies Appoints Ian Smith to its Board of Directors ENCINO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the appointment of Ian Smith to its Board of Directors, effective July 1, 2025. Mr. Smith brings with him over three decades of global leadership experience in financial services, with a proven track record in automotive finance, digital transformation and strategic growth. Most notably,...
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Import...
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) annou...
Lexicon to Present Data at the 85th Scientific Sessions of the America...
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes ...
Leading Chinese Automaker Expands Use of NETSOL’s Transcend Finance Pl...
Leading Chinese Automaker Expands Use of NETSOL’s Transcend Finance Platform Following Strategic Acquisition ENCINO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a global provider of business services and enterprise application solutions, today announced the continued expansion of its Transcend Finance platform by the financial division of one of China’s largest state-owned automotive manufacturers. This follows the automaker’s strategic acquisition of another domestic finance company, specifically to enhance its wholesale finance operations. The en...
Clearside Biomedical Announces Multiple Presentations to be Featured a...
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), a...
NETSOL Secures Product Expansion with UK Brokerage Charles and Dean
NETSOL Secures Product Expansion with UK Brokerage Charles and Dean The strategic move follows the successful integration of NETSOL's Flex and Dock solutions in August 2024 and marks a significant step in Charles and Dean's commitment to scaling operations and enhancing service delivery. ENCINO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, has announced that Charles and Dean, one of the United Kingdom's leading independent finance brokers, has expanded its adoption of NETSOL’...
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Health...
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering...
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2...
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors sectio...
NETSOL appoints Richard Howard as Advisory Board Member
NETSOL appoints Richard Howard as Advisory Board Member ENCINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, has announced the appointment of Richard Howard, a distinguished automotive executive with an extensive leadership track record at Daimler Financial Services, to its Advisory Board. While Richard joins NETSOL in the capacity of an Advisory Board Member, his involvement will go far beyond a traditional advisory role. He will play an active part in shaping the corporate st...
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Co...
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced details of its “SOtaglifloziN in Patients with...
Clearside Biomedical Announces First Quarter 2025 Financial Results an...
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Development Partners - - Use of Suprachoroidal Drug Delivery Featured in Over 15 Presentations at Major Ophthalmic Medical Meetings This Year - ALPHARETTA, Ga., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CLSD), a biophar...
NETSOL Technologies Reports Third Quarter Fiscal 2025 Results
NETSOL Technologies Reports Third Quarter Fiscal 2025 Results Total net revenues for Q3’25 increased by 13%, reaching $17.5 million, when compared with Q3’24.Total service revenue increased 24% in Q3’25, reaching $9.7 million, when compared with Q3,’24.Total subscription (SaaS and Cloud) and support revenues increased 10% to $7.9 million, compared to $7.1 million in the prior year period.Net profit for Q3’2025 was $1.4 million. ENCINO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ), a global business services and asset finance solutions provider, reported results ...
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results a...
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX), today reported financial re...
Clearside Biomedical Data Featured in Six Presentations at Association...
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that six presentations related to the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.